Monmouth Junction, NJ, United States of America

Ajit K Parhi

USPTO Granted Patents = 4 

 

Average Co-Inventor Count = 4.3

ph-index = 1

Forward Citations = 2(Granted Patents)


Location History:

  • Monmouth Junction, NJ (US) (2019)
  • New Brunswick, NJ (US) (2023 - 2024)

Company Filing History:


Years Active: 2019-2024

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Ajit K Parhi

Introduction

Ajit K Parhi is a notable inventor based in Monmouth Junction, NJ (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of antibacterial agents. With a total of four patents to his name, his work has had a meaningful impact on medical science.

Latest Patents

Among his latest patents, Ajit K Parhi has developed synthetic processes and synthetic intermediates that are useful for preparing the antibacterial agent TXA709. This invention focuses on creating effective compounds that can combat bacterial infections. Additionally, he has disclosed compounds of formula I, which serve as bacterial efflux pump inhibitors. These compounds, along with their salts, are crucial for developing new therapeutic compositions and methods.

Career Highlights

Throughout his career, Ajit K Parhi has worked with several prominent organizations. Notably, he has been associated with Taxis Pharmaceuticals, Inc. and Rutgers, the State University of New Jersey. His experience in these institutions has allowed him to advance his research and contribute to innovative solutions in the pharmaceutical industry.

Collaborations

Ajit has collaborated with several professionals in his field, including Ravi Ponnaiah and Anil Kumar Soni. These collaborations have fostered a productive environment for innovation and development in his research endeavors.

Conclusion

Ajit K Parhi's contributions to the field of pharmaceuticals through his patents and collaborations highlight his role as a significant inventor. His work continues to influence the development of new antibacterial agents and therapeutic methods.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…